title: Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience.
abstract: Extracorporeal photopheresis (ECP) is an established therapy for cutaneous T-cell lymphoma (CTCL). The objective of this study was to further explore the clinical efficacy of ECP combined with immunomodulatory agents. Eighteen patients with histologically proven CTCL were followed-up after therapy with ECP, mainly combined with interferon-α or bexarotene. A total of 61% of patients responded to therapy (n=11; CR: 5, PR: 6). Median survival was 51 months, progression free survival was 28 months and response duration was 29 ± 23.9 months. ECP combined therapy was highly effective or had a palliative effect in CTCL resistant to previous treatments.
authors.affiliation: 1st Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Greece. msiaka@med.uoa.gr
authors.forename: Marina P
authors.initials: MP
authors.lastname: Siakantaris
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Tsirigotis
authors.forename: Niki
authors.initials: N
authors.lastname: Stavroyianni
authors.forename: Kimon V
authors.initials: KV
authors.lastname: Argyropoulos
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Girkas
authors.forename: Vasiliki
authors.initials: V
authors.lastname: Pappa
authors.forename: Spiros
authors.initials: S
authors.lastname: Chondropoulos
authors.forename: Evangelia
authors.initials: E
authors.lastname: Papadavid
authors.forename: Ioanna
authors.initials: I
authors.lastname: Sakellari
authors.forename: Achilles
authors.initials: A
authors.lastname: Anagnostopoulos
authors.forename: Christina
authors.initials: C
authors.lastname: Antoniou
authors.forename: John
authors.initials: J
authors.lastname: Dervenoulas
mesh_terms: D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D016410:Lymphoma, T-Cell, Cutaneous / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D017893:Photopheresis / Q000379:methods*; D012878:Skin Neoplasms / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate
chemical_list: D007155:Immunologic Factors